Pandemic & Infectious Disease — 2026-04-02

Active Outbreak Tracker

Respiratory Viruses (COVID-19, Influenza, RSV) — United States

• Status: Winding down for the 2025–2026 season; CDC activity levels updated as of late March 2026.
• Key Development: CDC's respiratory illness data channel confirmed this week that it "does not anticipate producing additional outlook updates during the remainder of the 2025–2026 respiratory season." Rt estimates for COVID-19, influenza, and RSV across U.S. states continue to be monitored by the Center for Forecasting and Outbreak Analytics (CFA).
• Response: California continues RSV immunization with monoclonal antibodies (nirsevimab and clesrovimab) for eligible infants and children through April 30, 2026, with insurance coverage in place.

5 sources

cdc.gov

cdc.gov

cdc.gov

Measles Cases and Outbreaks | Measles (Rubeola) | CDC

cdc.gov

cdc.gov

cdc.gov

Global Measles Outbreaks | Global Measles Vaccination | CDC

cdc.gov

Respiratory Virus Activity Levels | Respiratory Illnesses | CDC

COVID-19 Vaccine Antigen Composition Review — Global

• Status: Active scientific review; May 2026 WHO advisory group meeting approaching.
• Key Development: WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) published its data requirements this week (dated March 30, 2026) for informing May 2026 deliberations on COVID-19 vaccine antigen composition. The group continues to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to infection and vaccination, and vaccine performance against circulating strains.
• Response: TAG-CO-VAC is soliciting specific data submissions from researchers and manufacturers ahead of the May deliberations, when updated vaccine strain recommendations are expected.

Norovirus — Global (Emerging Vaccine Watch)

• Status: No emergency outbreak declared, but multiple vaccine candidates in active development facing scientific and policy barriers.
• Key Development: A Medscape analysis published this week highlights that researchers are advancing several norovirus vaccine candidates — including oral tablet-based platforms, mRNA vaccines, and virus-like particle (VLP) technologies — but that these face significant scientific and policy hurdles before reaching approval.
• Response: No regulatory filings imminent; research teams are working to resolve challenges related to strain diversity and immune durability.

Vaccine & Treatment Pipeline

• COVID-19 Vaccine (Updated Antigen Composition) (Multiple Manufacturers): WHO TAG-CO-VAC formally outlined the types of data needed to guide May 2026 antigen composition decisions, marking the start of the pre-selection data collection phase. Final recommendations expected before northern hemisphere autumn immunization campaigns.

• Norovirus Vaccine Candidates (Multiple Developers — mRNA, VLP, Oral Platforms): Multiple vaccine candidates are progressing through research and early-stage development but face scientific hurdles including strain diversity (multiple genogroups circulate globally) and questions around durability of immune response. Policy frameworks for regulatory approval remain underdeveloped. No Phase 3 trial reads expected imminently.

• Reinforcement Learning–Optimized Disease Interventions (Academic Research): A study published in Scientific Reports (dated approximately 2 days ago) explored optimizing infectious disease intervention measures using reinforcement learning with UK COVID-19 epidemic data, offering potential future tools for real-time policy guidance during outbreaks.

1 sources

nature.com

nature.com

Expert Analysis

A newly published Lancet commission paper (approximately one week old, within the coverage window) is calling on global leaders to elevate spillover prevention at the upcoming 2026 UN High-Level Meeting on pandemic prevention, preparedness, and response. The Lancet–PPATS Commission on Prevention of Viral Spillover argues that reducing the risk of pandemics through primary prevention — stopping animal-to-human viral transmission before it occurs — must become a central pillar of global health security frameworks, not an afterthought. The commission contends that most pandemic preparedness investment to date has focused on response rather than upstream prevention of zoonotic spillover events.

The Lancet Infectious Diseases journal, which carries an impact factor of 29.5 as of 2026, has placed pandemic preparedness, emerging pathogens, antimicrobial resistance, and vaccine effectiveness at the top of its editorial priority list, reflecting where the global infectious disease research community is concentrating resources and attention. This mirrors the broader trajectory of institutional concern: with the UN High-Level Meeting approaching later in 2026, there is growing pressure on governments to translate political commitments into binding, funded mechanisms for both preparedness and primary prevention.

Separately, a rapid systematic review published this week in JMIR Public Health and Surveillance evaluated the effectiveness of contact tracing in reducing transmission during epidemic or pandemic responses. The review found that contact tracing, while a cornerstone intervention, has variable effectiveness depending on implementation speed, coverage, and the epidemiological characteristics of the pathogen in question — underscoring that no single non-pharmaceutical intervention can substitute for robust, integrated outbreak response systems.

Global Health Security

UN High-Level Meeting on Pandemic PPR (2026) — Spillover Prevention Push: The Lancet–PPATS Commission published a position paper this week urging that the 2026 UN High-Level Meeting on pandemic prevention, preparedness, and response explicitly include upstream viral spillover prevention — reducing the risk of animal-to-human transmission — as a primary policy objective. The commission argues this has been systematically underrepresented in existing global health security frameworks and international financing mechanisms.

CDC Respiratory Season Wrap-Up: CDC's data channel confirmed this week that it does not anticipate additional seasonal outlook updates for the 2025–2026 respiratory disease season, signaling a formal transition away from active winter respiratory virus surveillance urgency. CFA's real-time Rt estimates for COVID-19, influenza, and RSV continue to be published for all U.S. states.

California RSV Immunization Extension: The California Department of Public Health confirmed that RSV immunization with monoclonal antibodies (nirsevimab and clesrovimab) for eligible infants and young children will continue through April 30, 2026, with insurance coverage maintained — a state-level initiative to extend protection into the waning months of RSV season.

What to Watch Next

• WHO TAG-CO-VAC May 2026 Deliberations: The WHO advisory group's upcoming May meeting will produce updated COVID-19 vaccine antigen composition recommendations for the next immunization cycle. Data submissions from manufacturers and researchers are now being actively solicited — the outcome will shape vaccine formulations for hundreds of millions of doses globally. Watch for interim scientific summaries and manufacturer responses over the coming weeks.

• UN High-Level Meeting on Pandemic PPR: Scheduled for later in 2026, this meeting is drawing increasing expert attention. The Lancet–PPATS Commission's call to embed viral spillover prevention into binding international frameworks could influence whether the meeting produces enforceable commitments or aspirational declarations. Negotiations and preparatory texts will be worth monitoring closely.

• Norovirus Vaccine Regulatory Pathway: With multiple platforms (mRNA, VLP, oral tablet) in development and significant policy hurdles identified by experts, any regulatory filing announcement or Phase 2/3 trial initiation would represent a notable milestone in a disease area that has long lacked an approved vaccine, despite norovirus being the leading global cause of acute gastroenteritis.